Glucagon-like peptide-1 receptor agonists (GLP-1RA) are incretin-based therapies with demonstrated efficacy in glycemic control, weight reduction, and cardiovascular and renal protection
It is an investigational drug that is still under phase 3 clinical trials, in which the researchers are evaluating the safety, dosing, efficacy, and long-term outcome in a larger population
Other Weight Loss Medications Phentermine and phentermine-topiramate (Qsymia) for short-term and longer-term use in eligible patients Naltrexone-bupropion (Contrave) for patients with emotional or compulsive eating patterns Metformin for patients with insulin resistance or pre-diabetes contributing to weight gain Liraglutide (Saxenda) as an alternative injectable GLP-1 for patients who do not tolerate weekly injections Prescription weight loss medications are not appropriate for every patient
They work by increasing insulin secretion, decreasing appetite, and slowing gastric emptying
Others experience sulfur burps from day one that persist for several weeks before gradually improving